Application of reversed-phase thin layer chromatography and QSRR modelling for prediction of protein binding of selected β-blockers

Ciura, K., Kawczak, P., Greber, K. E., Kapica, H., Nowakowska, J., & Bączek, T.

Journal of pharmaceutical and biomedical analysis 176 (2019): 112767.

Chromatographic properties of sixteen β-blockers were studied using planar chromatography. The aim of presented study was to investigate influence of different organic solvents (acetonitrile, methanol, dioxin and tetrahydrofurane) on β-blockers' retention on C18 bonded silica gel stationary phase. Group of sixteen, diverse in terms of structure, beta blockers was used as a model set. The main goal of this study was to compare chromatographically estimated lipophilicity parameters with values obtained with the use of computational methods. Furthermore, in order to understand molecular mechanisms of retention better, quantitative structureretention relationships (QSRR) analysis was performed. The next step was focused on application of chromatographically obtained lipophilicity parameters for prediction of protein binding (PB), based on quantitative retention-activity relationships (QRAR) approach. The obtained results showed that reversed-phase thin layer chromatography (RP-TLC), especially with tetrafydrofurane used as an organic modifier of mobile phase, is a useful tool for lipophilicity estimation, as well as for prediction of β-blockers' biological properties. The QRAR model included C0 parameters for tetrahydrofuran-water as a mobile phase, as well as maximal projection area, and can be easily applied for prediction of systematically synthesized β-blockers structures' PB.

Application of reversed-phase thin layer chromatography and QSRR modelling for prediction of protein binding of selected β-blockers

Related Products

Catalog NumberCASProduct NamePrice
B0084-051384145108-58-3Dexmedetomidine HClInquiry
B0084-061561183814-30-4Formoterol fumarate dihydrateInquiry
B0084-06525929110-48-3Guanfacine hydrochlorideInquiry
B0084-081151104054-27-5AtipamezoleInquiry
B0084-182334223673-61-8MirabegronInquiry